Allergy testing may predict COPD Flare-Up risk
NCT ID NCT06518473
The trial has finished. Results may not be published yet.
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This study investigates whether allergic sensitivity, known as atopy, is associated with more frequent exacerbations in people with chronic obstructive pulmonary disease (COPD). Researchers will measure markers of allergy, such as IgE levels and skin prick test responses, in 100 adults aged 40-70 with COPD. The goal is to see if these allergic markers correlate with the number of flare-ups, which could help identify patients who might benefit from allergy-focused management.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Skin prick test and serum IgE measurement
- What this could lead to
- If a link is found, it could point toward allergy testing as a way to identify COPD patients at higher risk of flare-ups, potentially guiding more personalized care.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to all COPD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria
- Ages
-
40 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 40-70 years diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 criteria Exclusion Criteria: * Patients with known allergic diseases before enrollment * Patients with associated other chronic respiratory disorders * Patients with significant comorbidities that could influence respiratory function. * Recent respiratory infections or use of systemic corticosteroids within the last month before enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mohamed AbdElmoniem
Al Mansurah, 35516, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could heat pulses in the airways quiet a Smoker's cough?
- Can an mRNA vaccine shield the most vulnerable from RSV?
- Could simple breathing exercises be a new weapon against COPD and asthma?
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?